Gan & Lee Pharmaceuticals Co Ltd (stock code: 603087.SH), a global biopharmaceutical company, announced on Wednesday that it has received orphan drug status from the European Medicines Agency (EMA) for the investigational drug GLR2007 intended to treat gliomas neuroepithelial tumours that originate from glial cells in the central nervous system.

The company's present clinical development program for GLR2007, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, is exploring the treatment of advanced solid tumours that has the potential to offer treatment options for clinicians and patients.

The product has received Orphan drug status in the European Union based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products.